[ad_1]
The health
Globallookpress
Jiri Hubatka
Scientists from the University of Texas at Austin, United States, conducted the first clinical trial of a group of drugs aimed at destroying murine phenotype cells on volunteers.
Science Alert reports that the test results are encouraging and promising, with 14 volunteers whose unknown cause of pulmonary fibrosis led to rapid death. In three weeks, the patients received nine doses of dasatinib used in the treatment of leukemia and the kericetin compound, which is a component of many dietary supplements.
The product, consisting of dasatinib and kerissetin, has helped clear much damaged macrophages, but does not die and continues to produce biochemical signals, causing aging of other cells and the body in general.
The patients at the end of the test became able to walk better than before, in addition to a marked improvement in their health. They also did not experience the side effects of the treatment used.
According to the researchers, although this test is preliminary, but has examined the utility of the preparation in the treatment of aging diseases attributed to pulmonary disease of unknown reason.
The second test should involve 15 people with pulmonary fibrosis and 20 patients with chronic renal failure. If the results are positive and the effectiveness of the product is proven, it will be tested more widely.
Source: Linta. ro
[ad_2]
Source link
